Immucytal® in the prevention and treatment of recurrent upper respiratory tract infections in children: A randomized, placebo-controlled, double-blind study

International Journal of Immunotherapy

Volumn 16, Issue 3-4, 2000, Pages 67-75

  Giovannini, M ^a   Fiocchi, A ^a   Sala, M ^a   Fontana, P ^a   Fiori, L ^a   Silano, M ^a   Baldini, G ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; BIOMUNIL; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; OKT 3; OKT 4; OKT 8; PLACEBO; RIBOMUNYL; RIBOVAC;

ADOLESCENT; ARTICLE; CHILD; CHILD HEALTH CARE; CHILDHOOD DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSULTATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEALTH ECONOMICS; HOSPITALIZATION; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOSTIMULATION; IMMUNOTHERAPY; INCIDENCE; INFECTION PREVENTION; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RIBOSOME; SIDE EFFECT; TABLET FORMULATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

EID: 0034458216     PISSN: 02559625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Otitis media
2. Recurrent respiratory tract infections in pediatric patients
3. Epidemiology of otitis media
4. Frequency and severity of infections in day care
5. Prevention of recurrent ear, nose and throat infections in young children with Ribomunyl: A double-blind, placebo-controlled study
6. Acute inflammatory diseases of the middle ear
7. Respiratory infections in day care
8. Epidemiology of upper respiratory tract and bronchopulmonary infections. A study of 221 pathogens from 202 samples
9. Recurrent respiratory infections in childhood: Experience with a bacterial extract plus bacterial ribosomes (Immucytal®)
10. Immunoglobulin production in man stimulated by orally administered bacterial lysate (Broncho-Vaxom)
11. Prevention of bacterial respiratory infections using a ribosomal vaccine
12. Oral administration of streptococcal antigen coupled to cholera toxin B subunit evokes strong antibody responses in salivary glands and extramucosal tissues
13. Biological activity of bacterial cell wall components: Immunogenicity of an immunostimulating bacterial extract
14. The mucosal immune system. From fundamental concepts to vaccine development
15. Bacterial adherence and upper respiratory tract disease: A correlation between S. pyogenes attachment and recurrent throat infections
16. Cytokine and Ig-producing cells in mucosal effector tissues: Analysis of IL-5 and IFN-γ producing cells, T cells, T cell receptor expression and IgA plasma cells from mouse salivary gland-associated tissues
17. Immunoglobulin A (IgA): Molecular and cellular interactions in volved in IgA biosynthesis and immune response
18. Overview of the mucosal immune system
19. The common mucosal immune system and current strategies for induction of immune responses in external secretions
20. Stimulation of NK cells using Klebsiella pneumoniae membrane proteoglycans
21. Stimulation of cytotoxic and non-cytotoxic functions of natural killer cells by bacterial membrane proteoglycans and ribosomes
22. Chemotactic cytokine gene expression and production induced in human monocytes by membrane proteoglycans from Klebsiella Pneumoniae
23. Bacterial ribosomal immunostimulants prime alveolar macrophages in vivo to produce interleukin 1 in vitro
24. Effect of an in vivo immunostimulant treatment on PMN functions: Interaction with antibiotics in vitro
25. Immunostimulant effects on granulocyte functions during an acute respiratory infection
26. Antibody-producing cells in peripheral blood and tonsils after oral treatment of children with bacterial ribosomes
27. Clinical evaluation of ribosomal immunotherapy in recurrent respiratory infections: Results of a meta-analysis
28. Pharmacology of ribosomal immunotherapy
29. Inhibition of Streptococcus pneumoniae adhesion by specific salivary IgA after oral immunisation with a ribosomal immunostimulant
30. ® in the prevention of recurrent upper respiratory tract infections
31. Clinical experience with Biomunil tablets in children with recurrent respiratory infections
32. Prophylaxis of recurrent respiratory infections in children with a new immunomodulating agent
33. Prevention of recurrent ear, nose and throat infections with Ribomunyl tablets in children aged less than 5 years
34. Prevention of recurrent ear, nose and throat infections in young children with Ribomunyl: Double-blind, placebo-controlled study
35. Economic evaluation of immunoprophylaxis in children with recurrent ear, nose and throat infections
36. An economic analysis using ribosomal immunotherapy to treat children with recurrent upper respiratory tract infections